ShivaniSrivastavaMD

Oncology • Lawrence Township, NJ

Hematologic Oncology

Vice President, Cell Therapy Development, Bristol Myers Squibb

Join to view full profile

Dr. Srivastava is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Srivastava's full profile

Already have an account?

Office
Bristol Myers Squibb
3401 Princeton Pike
Lawrence Township, NJ 08648

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHResidency, Internal Medicine, 2003 - 2004
SUNY Upstate Medical UniversityResidency, Internal Medicine, 2001 - 2003
Kasturba Medical College ManipalClass of 2000

Certifications & Licensure

IN State Medical License 2008 - 2013

Clinical Trials

Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma Start of enrollment: 2010 Oct 01
Terminated
Phase 2

Publications & Presentations

PubMed

38 citations
Inhibition of LSD1 with Bomedemstat Sensitizes Small Cell Lung Cancer to Immune Checkpoint Blockade and T-Cell Killing.
Joseph B Hiatt, Holly Sandborg, Sarah M Garrison, Henry U Arnold, Sheng-You Liao
Clinical Cancer Research. 2022-10-14
3 citations
Treatment patterns and outcomes following disease progression on anti-PD-1 therapies for advanced melanoma.
Beth L Nordstrom, Melissa Hamilton, Jenna M Collins, Dennis Earle, Ying Zhang
Future Oncology. 2022-04-01
747 citations
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
Hussein A Tawbi, Dirk Schadendorf, Evan J Lipson, Paolo A Ascierto, Luis Matamala
The New England Journal of Medicine. 2022-01-06

Industry Relationships

Vice President, Bristol Myers Squibb